CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Liraglutide Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current, To Be Discontinued. First FDA posting: 2023-07-18. Latest FDA row update: 2026-09-22.
FDA lists 11 package records, with companies: Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals USA, Inc., Meitheal Pharmaceuticals Inc., Meitheal Pharmaceuticals, Inc., Novo Nordisk, Novo Nordisk Pharmaceutical Industries, LP, Novo Nordisk, Inc., Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. Package NDCs: 0143-9144-02, 0143-9144-03, 0169-2800-15, 0169-4060-12, 0169-4060-13, 0480-3667-20, 0480-3667-22, 0480-7250-46, 71288-563-84, 71288-563-85.
FDA shortage reason: Delay in shipping of the drug; Discontinuation of the manufacture of the drug
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Hikma Pharmaceuticals USA, Inc. | 0143-9144-02 | Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02) | Available | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0143-9144-03 | Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03) | Available | 2026-09-18 |
| Meitheal Pharmaceuticals, Inc. | 71288-563-84 | Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84) | Available | 2026-08-27 |
| Meitheal Pharmaceuticals, Inc. | 71288-563-85 | Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85) | Available | 2026-08-27 |
| Novo Nordisk, Inc. | 0480-3667-20 | Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20) | Available | 2026-09-22 |
| Novo Nordisk, Inc. | 0480-3667-22 | Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22) | Available | 2026-09-22 |
| Novo Nordisk, Inc. | 0169-2800-15 | Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) | Limited Availability | 2026-09-22 |
| Novo Nordisk, Inc. | 0169-2800-15 | Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) | Not stated | 2026-08-25 |
| Novo Nordisk, Inc. | 0169-4060-12 | Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12) | Limited Availability | 2026-09-22 |
| Novo Nordisk, Inc. | 0169-4060-13 | Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13) | Limited Availability | 2026-09-22 |
| Teva Pharmaceuticals USA, Inc. | 0480-7250-46 | Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46) | Not stated | 2026-05-14 |
Source facts
Grouped generic ingredient: Liraglutide Injection · 11 package records
Therapeutic categories: Endocrinology/Metabolism
Dosage forms: Injection
Routes: SUBCUTANEOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-07T20:06:35+00:00. Derived grouping is documented in this record's derivations.